XERS logo

Xeris Biopharma Holdings (XERS)

Profile

Full Name

Xeris Biopharma Holdings, Inc.

Ticker Symbol

XERS

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 21, 2018

Indexes

Not included

Website

http://www.xerispharma.com

Employees

394

Key Details

Price

$4.08(-6.85%)

Market cap

$628.08M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$203.07M(+23.89% YoY)

Annual EPS

-$0.37(+17.78% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$4.08
XERS price is $4.08

30-Day Relative Volume

0.46
XERS 30-day relative volume is 0.46

Price Performance

Price Most recent change

-6.85%
XERS price was down -6.85% on Apr 16, 2025

Price YTD change

+20.35%
XERS price is up +20.35% since January 1st

Price 1-year change

+129.21%
XERS price is up +129.21% year-on-year

Price 3-year change

+66.53%
XERS price is up +66.53% over the past 3 years

Price Range

Price All-time high

$27.98
XERS price is currently -85.42% below its historical high of $27.98

Price 3-year low

$0.97
XERS price is currently +320.62% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$628.08M
XERS market capitalization is $628.08 million

Market cap 3-year change

+89.15%
XERS market capitalization is up +89.15% over the past 3 years

Market cap All-time high

$903.63M
XERS market capitalization is currently -30.49% below its historical high of $903.63 million

Market cap sector rank

72.12%
XERS market capitalization is higher than 72.12% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+3.84%
XERS shares outstanding is up +3.84% year-on-year

Shares Outstanding 3-Year Change

+13.59%
XERS shares outstanding is up +13.59% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.10
XERS beta is 1.10

200-day SMA

$3.33
XERS price is currently +22.61% above its 200-day simple moving average

50-day SMA

$4.40
XERS price is currently -7.22% below its 50-day simple moving average

RSI

39.89
XERS 14-day relative strength index is 39.89

Volume

0.46
XERS 30-day relative volume is 0.46

ATR

$0.35
XERS average true range is $0.35

10-day Historical Volatility

94.43%
XERS 10-day historical volatility is 94.43%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$203.07M
XERS annual revenue is $203.07 million

Revenue Analysts estimate

$262.30M
XERS annual revenue is currently -22.58% lower than the consensus analysts' forecast

Revenue 1-year change

+23.89%
XERS annual revenue is up +23.89% year-on-year

Revenue Sector rank

63.94%
XERS annual revenue is higher than 63.94% of companies in Healthcare sector

EPS

EPS

-$0.37
XERS annual earnings per share is -$0.37

EPS Analysts estimate

-$0.10
XERS annual earnings per share is currently +270.00% higher than the consensus analysts' forecast

EPS 1-year change

+17.78%
XERS annual earnings per share is up +17.78% year-on-year

EPS Sector rank

72.07%
XERS annual earnings per share is higher than 72.07% of companies in Healthcare sector

Profit

Gross profit

$166.24M
XERS annual gross profit is $166.24 million

Gross margin

81.86%
XERS annual gross profit margin is 81.86%

Operating profit

-$33.65M
XERS annual operating income is -$33.65 million

Operating margin

-16.57%
XERS annual operating profit margin is -16.57%

Net income

-$54.84M
XERS annual net profit is -$54.84 million

Net margin

-27.00%
XERS annual net profit margin is -27.00%

Expenses

Total expenses

$236.72M
XERS annual total expenses is $236.72 million

Operating expenses

$199.88M
XERS annual total operating expenses is $199.88 million

Cost of goods sold

$36.83M
XERS annual cost of goods sold is $36.83 million

Selling, general & administrative expenses

$163.48M
XERS annual SGA is $163.48 million

Depreciation and amortization

$12.63M
XERS annual depreciation & amortization is $12.63 million

Interest expense

$30.48M
XERS annual interest expense is $30.48 million

Income tax

-$2.27M
XERS annual income tax is -$2.27 million

EBIT & EBITDA

EBIT

-$26.62M
XERS annual earnings before interest & taxes is -$26.62 million

EBITDA

-$13.99M
XERS annual EBITDA is -$13.99 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$323.06M
XERS annual total assets is $323.06 million

Non current assets

$155.40M
XERS annual long term assets is $155.40 million

Current assets

$167.66M
XERS annual total current assets is $167.66 million

Cash and cash equivalents

$71.62M
XERS annual cash & cash equivalents is $71.62 million

Accounts receivable

$40.41M
XERS annual accounts receivable is $40.41 million

Inventory

$48.17M
XERS annual inventory is $48.17 million

Liabilities

Total liabilities

$352.68M
XERS annual total liabilities is $352.68 million

Long term liabilities

$252.23M
XERS annual total long term liabilities is $252.23 million

Current liabilities

$100.44M
XERS annual total current liabilities is $100.44 million

Accounts payable

$2.29M
XERS annual accounts payable is $2.29 million

Debt

Total debt

$271.45M
XERS annual total debt is $271.45 million

Total debt 1-year change

+18.44%
XERS annual total debt is up +18.44% year-on-year

Long term debt

$250.26M
XERS annual long term debt is $250.26 million

Short term debt

$21.18M
XERS annual short term debt is $21.18 million

Equity & Capital

Shareholders equity

-$29.61M
XERS annual stockholders equity is -$29.61 million

Book value

-$29.61M
XERS annual book value is -$29.61 million

Retained earnings

-$671.86M
XERS annual retained earnings is -$671.86 million

Working capital

$67.22M
XERS annual working capital is $67.22 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$36.98M
XERS annual cash flow from operations is -$36.98 million

Cash from operations 1-year change

+21.36%
XERS annual cash flow from operations is up +21.36% year-on-year

Cash from investing

$4.88M
XERS annual cash flow from investing activities is $4.88 million

Cash from investing 1-year change

+181.33%
XERS annual cash flow from investing activities is up +181.33% year-on-year

Cash from financing

$36.17M
XERS annual cash flow from financing activities is $36.17 million

Cash from financing 1-year change

+2342.28%
XERS annual cash flow from financing activities is up +2342.28% year-on-year

CAPEX

CAPEX

$868.00K
XERS annual capital expenditures is $868.00 thousand

CAPEX 1-year change

-61.64%
XERS annual capital expenditures is down -61.64% year-on-year

Free Cash Flow

Free cash flow

-$37.85M
XERS annual free cash flow is -$37.85 million

Free cash flow 1-year change

+23.21%
XERS annual free cash flow is up +23.21% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

81.86%
XERS annual gross profit margin is 81.86%

Operating margin

-16.57%
XERS annual operating profit margin is -16.57%

Net margin

-27.00%
XERS annual net profit margin is -27.00%

ROA & ROE

ROA

-16.99%
XERS annual return on assets is -16.99%

ROE

185.16%
XERS annual return on equity is 185.16%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
XERS price to earnings ratio value is unknown

PE ratio Sector rank

-
XERS price to earnings ratio is unknown

PB Ratio

PB ratio

-21.21
XERS price to book ratio is -21.21

PB ratio Sector rank

1.65%
XERS price to book ratio is higher than 1.65% of companies in Healthcare sector

PS Ratio

PS ratio

3.09
XERS price to sales ratio is 3.09

PS ratio Sector rank

53.59%
XERS price to sales ratio is higher than 53.59% of companies in Healthcare sector

Enterprise value

Enterprise value

$827.90M
XERS enterprise value is $827.90 million

Enterprise value Sector rank

74.4%
XERS enterprise value is higher than 74.4% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-59.16
XERS EV/EBITDA is -59.16

EV/EBITDA Sector rank

1.91%
XERS EV/EBITDA is higher than 1.91% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.67
XERS annual current ratio is 1.67

Quick ratio

1.19
XERS annual quick ratio is 1.19

Leverage

Debt to equity

-7.84
XERS annual debt to equity ratio is -7.84

Interest coverage ratio

-0.87
XERS annual interest coverage ratio is -0.87

Risk & Stability

Piotroski F-Score

4
XERS piotroski f-score is 4

Altman Z-Score

-1.24
XERS altman z-score is -1.24

Analyst ratings

Recent major analysts updates

Mar 7, 25 Piper Sandler
Neutral
Mar 7, 25 Leerink Partners
Outperform
Mar 7, 25 HC Wainwright & Co.
Buy
Mar 7, 25 Craig-Hallum
Buy
Jan 29, 25 Jefferies
Buy
Nov 11, 24 Piper Sandler
Neutral
Nov 11, 24 HC Wainwright & Co.
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
May 31, 24 HC Wainwright & Co.
Buy
May 10, 24 Piper Sandler
Overweight

Institutional Ownership

Similar stocks

IMNM logo
Immunome (IMNM)
LENZ logo
LENZ Therapeutics (LENZ)
NUVB logo
Nuvation Bio (NUVB)
Bicara Therapeutics (BCAX)
EOLS logo
Evolus (EOLS)
CSTL logo
Castle Biosciences (CSTL)
DNTH logo
Dianthus Therapeutics (DNTH)
AVBP logo
ArriVent BioPharma (AVBP)
SLP logo
Simulations Plus (SLP)
  • What is the ticker symbol for Xeris Biopharma Holdings?
  • Does Xeris Biopharma Holdings pay dividends?
  • What sector is Xeris Biopharma Holdings in?
  • What industry is Xeris Biopharma Holdings in?
  • What country is Xeris Biopharma Holdings based in?
  • When did Xeris Biopharma Holdings go public?
  • Is Xeris Biopharma Holdings in the S&P 500?
  • Is Xeris Biopharma Holdings in the NASDAQ 100?
  • Is Xeris Biopharma Holdings in the Dow Jones?
  • When was Xeris Biopharma Holdings's last earnings report?
  • When does Xeris Biopharma Holdings report earnings?
  • Should I buy Xeris Biopharma Holdings stock now?

What is the ticker symbol for Xeris Biopharma Holdings?

The ticker symbol for Xeris Biopharma Holdings is NASDAQ:XERS

Does Xeris Biopharma Holdings pay dividends?

No, Xeris Biopharma Holdings does not pay dividends

What sector is Xeris Biopharma Holdings in?

Xeris Biopharma Holdings is in the Healthcare sector

What industry is Xeris Biopharma Holdings in?

Xeris Biopharma Holdings is in the Biotechnology industry

What country is Xeris Biopharma Holdings based in?

Xeris Biopharma Holdings is headquartered in United States

When did Xeris Biopharma Holdings go public?

Xeris Biopharma Holdings's initial public offering (IPO) was on June 21, 2018

Is Xeris Biopharma Holdings in the S&P 500?

No, Xeris Biopharma Holdings is not included in the S&P 500 index

Is Xeris Biopharma Holdings in the NASDAQ 100?

No, Xeris Biopharma Holdings is not included in the NASDAQ 100 index

Is Xeris Biopharma Holdings in the Dow Jones?

No, Xeris Biopharma Holdings is not included in the Dow Jones index

When was Xeris Biopharma Holdings's last earnings report?

Xeris Biopharma Holdings's most recent earnings report was on Mar 6, 2025

When does Xeris Biopharma Holdings report earnings?

The next expected earnings date for Xeris Biopharma Holdings is May 9, 2025

Should I buy Xeris Biopharma Holdings stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page